New medicine for two types of pulmonary fibrosis
Submitted by Anonymous (not verified) on 22 May 2026 - 11:00
New medicine for two types of pulmonary fibrosis
First medicine to treat rare uncontrolled growth of body tissues
Submitted by Anonymous (not verified) on 22 May 2026 - 11:00
First medicine to treat rare uncontrolled growth of body tissues
First oral GLP-1 treatment for weight management
Submitted by Anonymous (not verified) on 22 May 2026 - 11:00
First oral GLP-1 treatment for weight management
Overview of (invented) names reviewed in April 2026 by the Name Review Group (NRG) adopted at the CHMP meeting of 21 May 2026
Submitted by Anonymous (not verified) on 22 May 2026 - 11:00
Overview of (invented) names reviewed in April 2026 by the Name Review Group (NRG) adopted at the CHMP meeting of 21 May 2026
Human medicines European public assessment report (EPAR): Veblocema, infliximab, Status: Application withdrawn
Submitted by Anonymous (not verified) on 22 May 2026 - 11:00
Human medicines European public assessment report (EPAR): Veblocema, infliximab, Status: Application withdrawn
Summary of opinion: Maviret, 21/05/2026 Positive
Submitted by Anonymous (not verified) on 22 May 2026 - 11:00
Summary of opinion: Maviret, 21/05/2026 Positive
Summary of opinion: Palynziq, 21/05/2026 Positive
Submitted by Anonymous (not verified) on 22 May 2026 - 11:00
Summary of opinion: Palynziq, 21/05/2026 Positive
Summary of opinion: Wegovy, 21/05/2026 Positive
Submitted by Anonymous (not verified) on 22 May 2026 - 11:00
Summary of opinion: Wegovy, 21/05/2026 Positive
Summary of opinion: Erbitux, 21/05/2026 Positive
Submitted by Anonymous (not verified) on 22 May 2026 - 11:00
Summary of opinion: Erbitux, 21/05/2026 Positive
Summary of opinion: Erbitux, 21/05/2026 Positive
Submitted by Anonymous (not verified) on 22 May 2026 - 11:00
Summary of opinion: Erbitux, 21/05/2026 Positive